Physician profile
Mark D Tyson
NPI 1346568508
$34,038.38
in general payments reported to CMS, 2019-2025
21 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2021: $303 · 2022: $2,215 · 2023: $586 · 2024: $1,494 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,097.50 |
| Food and Beverage | $2,190.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $16,557.82 | 2019-2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals Lp | $5,448.52 | 2024-2025 | Imfinzi |
| Urogen Pharma, INC. | $5,203.90 | 2022-2025 | |
| Astellas Pharma US INC | $2,353.03 | 2025 | Padcev |
| Photocure INC | $2,118.77 | 2019-2024 | Cysview |
| Janssen Biotech, INC. | $385.04 | 2024-2025 | Erleada, Akeega |
| Intuitive Surgical, INC. | $303.30 | 2021 | |
| Janssen Research & Development, LLC | $280.00 | 2022-2023 | |
| Karl Storz Endoscopy-America | $210.34 | 2019-2022 | |
| Genentech, INC. | $201.88 | 2019 | |
| Seagen INC. | $176.27 | 2022-2023 | Padcev |
| Edap Technomed INC | $171.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.21 | 2023 | |
| Immunitybio, INC. | $139.59 | 2025 | |
| Axonics, INC. | $139.53 | 2024 | Axonics, Bulkamid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $100.06 | 2019 | |
| Comsort, INC | $100.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.